- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- XOMA to Present at Upcoming Investor Conferences in March
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
- XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
- XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
More ▼
Key statistics
On Friday, XOMA Corp (X0M:FRA) closed at 23.00, -1.71% below its 52-week high of 23.40, set on Apr 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.80 |
---|---|
High | 23.00 |
Low | 22.80 |
Bid | 23.00 |
Offer | 23.80 |
Previous close | 23.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 11.64m |
Free float | 11.59m |
P/E (TTM) | -- |
Market cap | 295.65m USD |
EPS (TTM) | -4.04 USD |
Annual div (ADY) | 2.00 EUR |
---|---|
Annual div yield (ADY) | 8.71% |
Div ex-date | Apr 02 2024 |
Div pay-date | Apr 15 2024 |
Data delayed at least 15 minutes, as of Apr 26 2024 14:29 BST.
More ▼